Axsome Therapeutics, Inc. (LON:0HKF)
133.50
+7.38 (5.85%)
At close: Oct 20, 2025
Axsome Therapeutics Revenue
Axsome Therapeutics had revenue of $150.04M USD in the quarter ending June 30, 2025, with 72.13% growth. This brings the company's revenue in the last twelve months to $495.03M, up 69.83% year-over-year. In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth.
Revenue (ttm)
$495.03M
Revenue Growth
+69.83%
P/S Ratio
13.19
Revenue / Employee
$724.79K
Employees
683
Market Cap
4.77B GBP
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 385.69M | 115.09M | 42.53% |
Dec 31, 2023 | 270.60M | 220.56M | 440.80% |
Dec 31, 2022 | 50.04M | - | - |
Dec 31, 2021 | - | - | - |
Dec 31, 2020 | - | - | - |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
AstraZeneca | 41.24B |
GSK plc | 31.63B |
Haleon | 11.02B |
Smith & Nephew | 4.33B |
Hikma Pharmaceuticals | 2.35B |
ConvaTec Group | 1.72B |
Spire Healthcare Group | 1.55B |
Genus | 672.80M |
Axsome Therapeutics News
- 11 days ago - Axsome Therapeutics' Strong Growth And Expanding Pipeline: Why I Assign A Buy Rating - Seeking Alpha
- 11 days ago - Axsome Therapeutics (AXSM) Supports Mental Illness Awareness Week - GuruFocus
- 12 days ago - Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community - GlobeNewsWire
- 14 days ago - Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3 - GlobeNewsWire
- 19 days ago - AXSM: New 'Buy' Rating from B. Riley Securities with $179 PT | AXSM Stock News - GuruFocus
- 4 weeks ago - Axsome Therapeutics, Inc. (AXSM) Presents at TD Cowen's 5th Annual Novel Mechanisms in Neuropsychiatry & Epilepsy Summit Transcript - Seeking Alpha
- 4 weeks ago - Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025 - GlobeNewsWire
- 5 weeks ago - Axsome Therapeutics Stock Sees RS Rating Rise To 82 - Investor's Business Daily